What is ELIQUIS?
ELIQUIS (apixaban) is a prescription blood thinner used to reduce the risk of stroke and blood— clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. This type of irregular heartbeat can cause blood clots to form, which may lead to a stroke.
ELIQUIS can play an important role for people with AFib not caused by a heart valve problem. While ELIQUIS can't regulate your irregular heartbeat or treat symptoms, it can reduce the risk of stroke by helping to prevent clots from forming.
Selected Important Safety Information
Do not stop taking ELIQUIS without talking to the doctor who prescribed it for you. Stopping ELIQUIS increases your risk of having a stroke.
ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your doctor will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.
ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting.
Please read additional Important Safety Information and ELIQUIS Indication below.
How does ELIQUIS work?
ELIQUIS works by blocking Factor Xa, which is a blood-clotting factor critical to the blood-clotting process. By blocking Factor Xa, ELIQUIS lowers the chance of blood clots forming and decreases the risk of having a stroke in people with atrial fibrillation not caused by a heart valve problem.
ELIQUIS is supported by extensive cinical research
ELIQUIS was studied in 2 clinical trials to evaluate stroke risk due to AFib not caused by a heart valve problem. Approximately 24,000 people participated in the 2 studies, including more than 11,000 people who took ELIQUIS.
The first trial compared ELIQUIS to warfarin in people with AFib not caused by a heart valve problem and who had at least one additional risk factor for stroke. The second trial compared ELIQUIS to aspirin in people with AFib not caused by a heart valve problem who were not suitable for warfarin treatment and who had at least one additional risk factor for stroke.
As a result of these clinical trials, ELIQUIS was approved to reduce the risk of stroke and blood clots in people with AFib not caused by a heart valve problem.
Next: Reasons to Rethink Warfarin